SYDNEY, AUSTRALIA, 29 SEPTEMBER 2022 – Pfizer has announced the Pfizer-BioNTech COVID-19 vaccine (COMIRNATYTM) has been granted provisional approval by the Therapeutic Goods Administration (TGA) for use in children aged 6 months to under 5 years old.
While children who experience COVID-19 are less likely to develop severe illness compared with adults, they are still at risk of developing severe illness and complications from COVID-19, including Multisystem Inflammatory Syndrome, and long COVID.
Children under 5 years also have a higher risk of diseases that overlap with COVID-19 including pneumonia, and other viral upper respiratory tract infections.
COVID-19 remains an everyday part of our lives, and the potential for continued spread of COVID-19 in childcare and preschools also remains.
“Today’s provisional approval is an important reminder for parents to speak to their healthcare professional about COVID-19 vaccination,” said Dr Krishan Thiru, Pfizer Australia and New Zealand’s Medical Director.
For children 6 months to 5 years old, a primary vaccination course consists of three doses of the COMIRNATY vaccine.
About Pfizer Australia: Breakthroughs That Change Patients’ LivesTM
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines.
Consistent with our responsibility as one of the world’s leading biopharmaceutical companies, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. F